ReviewAustralian prescriber2022
Diuretics in the management of chronic heart failure: when and how.
Review in Australian prescriber, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Risk factors of thirst amongst critically ill and patients undergoing surgery: a systematic review and meta-analysis.Irish journal of medical science · 2026Pooled it
- Cardiopulmonary Remodeling In Nondiabetic Patients with Systolic Heart Failure Using Sodium-Glucose Cotransporter 2 Inhibitors: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials.Current cardiology reviews · 2026Pooled it
- Comparative analysis of the addition of empagliflozin versus doubling the furosemide dose in decompensated heart failure.Cardiovascular drugs and therapy · 2025Trial
- Efficacy of ambulatory intravenous diuresis for chronic heart failure patients: Insights from the DEA-HF trial.ESC heart failure · 2025Trial
- Decisions in Diuretic Resistance: Oral or Subcutaneous Furosemide in Advanced Ambulatory Heart Failure?Biomedicines · 2026Article
- Pharmacological assessment of drugs retained in the 1Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
- Prevalence and characterization of heart failure in Aragon, Spain (ICAR study).Frontiers in cardiovascular medicine · 2026Article
- Acute kidney injury in acute decompensated heart failure: clinical predictors and In-hospital outcomes at a tertiary center.Annals of medicine · 2025Observational
- From Plants to Protection: Cardiorenal Benefits in Non-Diabetic Chronic Kidney Disease and Heart Failure.Molecules (Basel, Switzerland) · 2025Review
- Precision Medicine: Therapeutically Targeting Mitochondrial Alterations in Heart Failure.JACC. Basic to translational science · 2025Review
- Exploring safety of down-titrating diuretics in heart failure management.European journal of heart failure · 2025Article
- Impact of Lifestyle Modifications Along With Pharmacological Treatment of Heart Failure: A Narrative Review.Cureus · 2025Review
- Pharmacogenomics and its Role in Cardiovascular Diseases: A Narrative Literature Review.Current cardiology reviews · 2025Review
- Heart failure: mechanistic insights and precision therapeutic strategies.Frontiers in cardiovascular medicine · 2025Review
- Fluid status assessment in heart failure patients: pilot validation of the Maastricht Decompensation Questionnaire.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2025Article
- Real-world effectiveness and safety of torsemide and spironolactone fixed dose combination in Indian heart failure patients (RESTORE-HF study): a prospective, multicenter, observational study.Therapeutic advances in cardiovascular diseaseObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure is an increasingly prevalent condition resulting in recurrent hospitalisations and significant mortality and morbidity. The management of heart failure has evolved, and multiple drugs have an established mortality benefit in heart failure with reduced ejection fraction. Although the focus should be on ensuring that patients are treated with the maximum tolerated doses of these guideline-directed therapies, diuretics continue to play a key role in the management of clinical congestion in all forms of heart failure. Clinicians play a key role in heart failure management. Familiarity with the role of diuretics and their dosing and monitoring is critical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.